Tolerance Bio

Thank you, Bryan Kennedy and BioBuzz, for spotlighting our mission and innovative work! It’s an exciting time as we push the boundaries of science with the support of our recently announced $20.2 million rolling seed financing round completion. At Tolerance Bio, we’re committed to harnessing thymus-based therapies and look forward to driving transformative advancements in immune tolerance.

We are thrilled to announce the completion of an oversubscribed $20.2 million rolling seed financing round, along with the formation of our Scientific Advisory Board (SAB) to support our work in advancing thymus-based therapies for immune-mediated diseases. These exciting milestones help advance our mission of transforming the treatment landscape for these diseases by preserving, restoring, and manipulating the #thymus – the body’s master regulator of #immunetolerance.     We’re proud to have world-class leaders in thymus biology, #immunology, #oncology, and drug development on our SAB as we move to advance our allogeneic iPSC-based thymus cell therapy platform and pharmacological thymus therapies.     Learn more about the news and the members of our SAB here: https://lnkd.in/eYByUQrJ

Join Justin Vogel, our Chief Financial Officer, for a dynamic discussion tomorrow on The Art of Fundraising, hosted by Life Sciences Pennsylvania. Joined by Laura Tadvalkar, PhD, Managing Director at RA Capital Management, they will share insights on navigating the fundraising journey and exploring strategies for success at every stage of the fundraising lifecycle. Moderated by Barb Carlin CPA, MBA, from Danforth Advisors, this conversation will also be available as a recording. Register for the panel here: https://lnkd.in/eigJQYzC #ArtofFundraising #Investments #LifeSciences #Biotech

We’re proud to announce the completion of a $17.2 million seed financing round. These funds will support advancing our thymus-based therapies, moving them towards clinical trials for the treatment of immune-mediated diseases caused by abnormalities in #immunetolerance such as cancer, autoimmunity, transplant rejection, and more. Learn more about the news and our commitment to making a meaningful impact in the lives of these patients: https://lnkd.in/dd2mtAzG   #immunetolerance #thymushealth #thymus #diseaseprevention #celltherapy, #advancedtherapeutics #regenerativemedicine #longevity

We are excited to share that our Founder and CEO, Francisco Leon, will be speaking at the Sino-American Pharmaceutical Professionals Association (SAPA) Annual Meeting. The event’s theme, “Redefining Medicine: Navigating Resilience, Transforming Lives,” aligns with Tolerance Bio’s mission to develop transformative medicines that restore immune balance and address the root cause of autoimmune diseases. Francisco will be sharing insights from his extensive experience in drug repositioning, including examples from his work at Celimmune, Provention Bio, and our current innovations at Tolerance Bio. For more details, visit the SAPA Annual Meeting website: https://lnkd.in/eJv-JwN6 #SAPA2024 #SAPA #SAPAAC  #biotech #drugdevelopment #healthcareinnovation

This week, we are proud to have our CEO, Francisco Leon, present at the 20th International Celiac Disease Symposium, where he will provide an update on pharmaceutical research and development in #celiacdisease. He will also share more about our pioneering approach to preventing and treating celiac and other immune-related diseases by focusing on the thymus, the body’s master regulator of immune tolerance. #ICDS2024 #biotech